Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

PRFX - PAINREFORM LTD.

3.06
0.080   2.614%

Share volume: 34,279
Last Updated: 03-07-2025
Pharmaceutical Products/Pharmaceutical Preparations: 0.03%

PREVIOUS CLOSE
CHG
CHG%
$2.98
0.08
0.03%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
8%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 20%
Performance
5 Days
2.68%
1 Month
3.38%
3 Months
2.00%
6 Months
222.11%
1 Year
47.26%
2 Year
-40.70%
Key data
Stock price
$3.06
P/E Ratio 
0.00
DAY RANGE
$2.92 - $3.06
EPS 
N/A
52 WEEK RANGE
$0.20 - $16.63
52 WEEK CHANGE
$53.00
MARKET CAP 
1.567 M
YIELD 
N/A
SHARES OUTSTANDING 
7.026 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.14
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$79,020
AVERAGE 30 VOLUME 
$2,402,096
Company detail
CEO: Ilan Hadar
Region: US
Website: painreform.com
Employees: 4
IPO year: 2020
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

PainReform Ltd. engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair.

Recent news